Caris Research
Equity Research By Leo Carpio
Click here to sign up for a Caris Research Account
8/09/2010
(ECLP) ECLP (Caris Update) 2Q10 EPS Beat and Strong 1H10 Bookings; Allscripts Deal Contains Significant Upside Potential
No introduction text is currently available for this report.
8/06/2010
(EM) EM (Caris Price Target Change) Healthcare Utilization Trends Drives In Line EPS. We Lower PT to $17. EM Shares worth a look.
No introduction text is currently available for this report.
8/04/2010
(ECLP) ECLP (Caris Update) 2Q10 Preview – Noisy Q Overlooked with Focus on MDRX Deal
No introduction text is currently available for this report.
8/04/2010
(ATHN) ATHN (Caris Update) Client Meetings – Cracking the 2011 Riddle
No introduction text is currently available for this report.
8/04/2010
(EM) EM (Caris Update) 2Q10 Preview – In Line Q EPS & Revised 2010 Guidance
No introduction text is currently available for this report.
8/02/2010
(CPSI) CPSI (Caris Price Target Change) 2Q10 Review – Obama HCIT Program Spurs Small Hospital Capital Spend Resurgence
No introduction text is currently available for this report.
8/02/2010
(QSII) QSII (Caris Price Target Change) FY1Q11 Results – Calm before the Obama HCIT Storm, Old: $66, New: $64
No introduction text is currently available for this report.
7/30/2010
(CPSI) CPSI (Caris Update) 2Q10 Results – First Glance; EPS Beat and Good 3Q10 Guidance
No introduction text is currently available for this report.
7/29/2010
(CERN) CERN (Caris Update) 2Q EPS Beat, Strong Bookings & Raise 2010 Guidance: Investors Should Be Pleased
No introduction text is currently available for this report.
7/27/2010
(QSII) QSII (Caris Update) FY1Q11 Results; Eyes on the Obama HCIT Prize
No introduction text is currently available for this report.
Depending on the investment objectives and financial information specific to your situation, the investments discussed or recommended on this website may or may not be suitable for you. It is your responsibility to consider any investment decision carefully. The information contained on this website should not be construed as advice designed to meet the particular needs of any investor. Past performance is not necessarily indicative of future performance, and does not guarantee future results. The price and/or value of any security noted directly or indirectly on this website may fluctuate adversely to your interests, and/or those of other investors. Caris & Company accepts no liability whatsoever for loss or damage of any sort arising out of use of all or part of any information on this website.